CONMED's stock narrative has shifted as the consensus analyst price target has been reduced from $61 to $56. This reflects more cautious sentiment among market watchers. This reassessment comes alongside a higher discount rate and slightly softened revenue growth expectations, indicating heightened concerns about risk and near-term performance. Investors should keep an eye on upcoming updates to stay informed about how evolving analyst perspectives may affect the outlook for CONMED.

Stay updated as the Fair Value for CONMED shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on CONMED.

Recent analyst commentary reflects a mix of optimism and caution around CONMED as price targets have been revised and research firms weigh in on the company’s outlook. While there is a consensus move toward more measured expectations, viewpoints differ in emphasis, reflecting the balance between CONMED’s growth prospects and execution risks.

???? Bullish Takeaways

Analysts have highlighted the company's efforts to manage costs and improve margins, with Barclays specifically identifying that margin initiatives remain on track.

Favorable trends in certain end-markets continue to be acknowledged. Barclays notes that municipal and non-residential segments are holding steady, providing some resilience amid broader challenges.

JPMorgan has maintained an Overweight rating, signaling continued confidence in the company’s medium-term growth potential. However, they lowered their price target to $54 from $64 following their model update after earnings.

???? Bearish Takeaways

Multiple analysts have trimmed their price targets, underscoring more cautious sentiment around the company’s valuation and growth trajectory. Truist reduced its target to $50 from $56, while Citi and JPMorgan also lowered their respective outlooks.

Slower momentum in residential business segments and rising selling, general, and administrative (SG&A) costs were highlighted by Truist as key contributors to recent performance shortfalls.

Barclays mentioned significantly weaker new residential lot development and ongoing cost inflation as reasons for cutting their price target to $65 from $69. Certain positive trends persist despite these factors.

Analysts point out that while management has revised guidance downward, the adjustment is consistent with broader market conditions rather than signaling a new negative trend, according to Truist.

Overall, the analyst community remains attentive to how CONMED executes against near-term challenges, with strong market positions in select niches but a closely monitored cost and demand environment driving both positive and negative revisions to valuation outlooks.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

CONMED revised its full-year 2025 earnings guidance, now projecting revenue between $1.365 billion and $1.372 billion. This reflects a slightly narrowed outlook compared to the previous range.

The company noted that recently announced tariffs are expected to negatively impact fourth quarter 2025 earnings per share by approximately $0.07.

CONMED's Board of Directors has suspended the quarterly cash dividend. This decision was made alongside the extension of the share repurchase program.

The company has completed the repurchase of 6,123,353 shares since the initiation of its buyback program in 2005, representing 21.23% of total shares and amounting to $162.54 million in repurchases.

Consensus Analyst Price Target has been reduced from $61 to $56, indicating a reassessment of expected upside.

Discount Rate has risen from 8.55% to 9.17%, which signifies increased perceived risk in future cash flows.

Revenue Growth expectations have edged lower from 5.69% to 5.33% annually.

Net Profit Margin is projected to improve, increasing from 9.84% to 11.25%.

The future P/E multiple has declined from 15.71x to 12.75x. This reflects a more conservative valuation outlook.

Narratives transform investing by letting you tell the story behind the numbers. On Simply Wall St, a Narrative blends your perspective on a company with forecasts for revenue, profit, and fair value. This approach makes it easy for anyone to connect business developments to real financial outcomes. Narratives update automatically as new information arrives, helping you compare fair value to current price and decide when to act, all within the Community page used by millions of investors.

Interested in seeing the full story for CONMED? Read the original narrative here to stay up to date on:

How CONMED's leadership in minimally invasive and robotic surgeries is driving recurring revenue growth and creating new global opportunities.

The impact of operational improvements and robust buyback activity on profit margins and shareholder value.

Which supply chain, spending, and competitive risks could challenge CONMED’s march toward higher earnings and fair value estimates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com